US 7625927 B2 - Method Of Treating Glaucoma - The Lens - Free & Open Patent and Scholarly Search

Method Of Treating Glaucoma

Published: Dec 1, 2009
Earliest Priority: Feb 27 2006
Family: 3
Cited Works: 39
Cited by: 14
Cites: 20
Additional Info: Cited Works Full text Published

Abstract

Described are methods for the treatment of ocular hypertension or glaucoma comprising administering a pharmaceutically effective amount of one or more compounds that inhibit the enzyme EgLN-3. Certain embodiments of the invention combine the use of EgLN-3 with other glaucoma treatment agents. The compounds of the invention may be formulated in compositions comprising pharmaceutically acceptable carriers.

Claims

A method for the treatment of a patient with ocular hypertension or glaucoma, which comprises administering to said patient in an ophthalmic formulation a pharmaceutically effective amount of a compound that inhibits the enzyme EgLN-3, and wherein the compound is selected from the group consisting of: wherein:
R is H, C_1-6straight chain or branched alkyl, phenyl, or benzyl, or CO₂R forms a salt of formula CO₂⁻M⁺, with M⁺ being Li⁺, Na⁺, K⁺, or NH₄⁺; and

R¹is H, C(O)CH₃, or C(O)C₆H₅.
The method of claim 1, wherein the compound is selected from the group consisting of: wherein:
R is H, H, CH₃, C₂H₅, or i-C₃H₇; and

R¹is H or C(O)CH₃.
The method of claim 1, wherein the compound is administered in an implant.
The method of claim 1, wherein the compound is administered as an intraocular injection.
The method of claim 1 wherein the compound is administered topically to the eye in a composition comprising a pharmaceutically acceptable carrier.
The method of claim 5 wherein the pharmaceutically effective amount of the compound in the composition is from 0.001 to 2% (w/v).
The method of claim 6 wherein the pharmaceutically effective amount is from 0.01 to 1% w/v).
The method of claim 5, wherein the pharmaceutically acceptable carrier comprises one or more ingredients selected from the group consisting of surfactants; tonicity agents; buffers; preservatives; co-solvents; gelling agents, vehicles, water, penetration enhancers, and viscosity building agents.
The method of claim 1 wherein said administering further comprises administering said one or more compounds together with or separate from at least one glaucoma treatment agent selected from the group consisting of:
β-blockers, prostaglandin analogs, carbonic anhydrase inhibitors, α₂agonists, miotics, rho kinase inhibitors and neuroprotectants.